UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours

Cardiovascular research, 2010-04, Vol.86 (1), p.12-19

2010

Volltextzugriff (PDF)

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

Journal of translational medicine, 2010-06, Vol.8 (1), p.56-56, Article 56

2010

Volltextzugriff (PDF)

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Clinical cancer research, 2007-06, Vol.13 (11), p.3333-3338

2007

Volltextzugriff (PDF)

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

Cancer Immunology, Immunotherapy, 2013-03, Vol.62 (3), p.605-614

2013

Volltextzugriff (PDF)

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Molecular oncology, 2011-04, Vol.5 (2), p.164-182

2011

Volltextzugriff (PDF)

Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications

Journal of cellular physiology, 2007-08, Vol.212 (2), p.330-344

2007

Volltextzugriff (PDF)

“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015

Cancer Immunology, Immunotherapy, 2016-11, Vol.65 (11), p.1423-1431

2016

Volltextzugriff (PDF)

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma

Journal of cellular physiology, 2010-05, Vol.223 (2), p.352-358

2010

Volltextzugriff (PDF)

Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention

Cancer Immunology, Immunotherapy, 2010-03, Vol.59 (3), p.487-488

2010

Volltextzugriff (PDF)

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer

Cancer Immunology, Immunotherapy, 2012-09, Vol.61 (9), p.1599-1608

2012

Volltextzugriff (PDF)

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010

Cancer Immunology, Immunotherapy, 2011-06, Vol.60 (6), p.901-907

2011

Volltextzugriff (PDF)

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

Cancer Immunology, Immunotherapy, 2010-06, Vol.59 (6), p.963-969

2010

Volltextzugriff (PDF)

5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story

Cancer research (Chicago, Ill.), 2007-03, Vol.67 (6), p.2900-2900

2007

Volltextzugriff (PDF)

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009

Cancer Immunology, Immunotherapy, 2010-12, Vol.59 (12), p.1895-1901

2010

Volltextzugriff (PDF)

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward

Journal of translational medicine, 2008-02, Vol.6 (1), p.8-8, Article 8

2008

Volltextzugriff (PDF)

“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

Cancer Immunology, Immunotherapy, 2015-01, Vol.64 (1), p.131-135

2015

Volltextzugriff (PDF)

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012

Cancer Immunology, Immunotherapy, 2013-12, Vol.62 (12), p.1851-1858

2013

Volltextzugriff (PDF)

Epigenetically regulated tumor-associated antigens in melanoma

Expert Review of Dermatology, 2009-04, Vol.4 (2), p.145-154

2009

Volltextzugriff (PDF)

Abstract A256: Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A256-A256

2013

Volltextzugriff (PDF)

Abstract 680: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.680-680

2013

Volltextzugriff (PDF)

Immunomodulatory activity of SGI-110, a 5-aza-2â[euro]²-deoxycytidine-containing demethylating dinucleotide

Cancer immunology, immunotherapy, 2013-03, Vol.62 (3), p.605

2013

Volltextzugriff (PDF)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study

Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P107-P107, Article P107

2013

Volltextzugriff (PDF)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment

Journal for immunotherapy of cancer, 2013-11, Vol.1 (Suppl 1), p.P71-P71

2013

Volltextzugriff (PDF)

Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein

The Journal of immunology (1950), 2005-02, Vol.174 (4), p.2404-2411

2005

Volltextzugriff (PDF)

Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens

Tumor‐Associated Antigens, 2009, p.143-160

2009

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(25)
Buchkapitel
(2)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications

“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma

Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008

5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward

“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012

Epigenetically regulated tumor-associated antigens in melanoma

Abstract A256: Epigenetic priming with novel hypomethylating agent SGI-110 improved antitumor activity of CTLA-4 blockade in a syngenic mouse model

Abstract 680: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent, in hematologic malignancies

Immunomodulatory activity of SGI-110, a 5-aza-2â[euro]²-deoxycytidine-containing demethylating dinucleotide

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment

Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein

Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens

Suchergebnisse filtern